Sensus Drug Development Corp., Shearwater Polymers Inc. deal

Sensus licensed Shearwater's polyethylene glycol (PEG) technology for the pegylation of Sensus' Somavert pegvisomant (formerly Trovert, or B2036-PEG) human growth hormone receptor antagonist, which has completed Phase III testing to treat acromegaly. Shearwater will receive upfront payments, rights to manufacture the PEG reagent and a share of product revenues. ...